RNA vaccine approach based on a novel split-vector system using trans-amplifying RNA (taRNA) or self-amplifying (saRNA) encoding HA antigen.

mRNA vaccine (mHAs) encoding the HA stem antigen of the influenza A (H1N1) virus.

Uses N-terminal extracellular region of the influenza virus M2 protein (M2e) as the target antigen; constructed two optimized M2e DNA vaccines (p-tPA-p3M2e and p-p3M2e) with increased antigenic epitope density and enhanced antigen secretion.

mRNA vaccine encoding influenza hemagglutinin (HA), nucleoprotein (NP), and three tandem repeats of matrix protein 2 (3M2e).

An mRNA vaccine platform that delivers NA and HA as a single open reading frame (ORF) to enable expression of multiple unmodified antigens from a single mRNA, using a unique glycoprotein organization with an artificial furin cleavage site and 2A ribosome-skipping sequences.

A multivalent influenza mRNA lipid nanoparticle (LNP) vaccine with mRNAs of hemagglutinins from influenza H1N1 and H3N2 viruses, matrix protein 1, and nucleoprotein, adjuvanted with cGAMP

Heterologous sequential mRNA LNP priming followed by intranasal protein nanoparticle boosting immunization to confer optimal cross-protection against antigenically drifted and shifted influenza strains.

See also Georgia State University’s, HA/GP nanoparticles and cGAMP-adjuvanted multivalent mRNA vaccines

mRNA construct encoding NP; administered intranodally; aimed at inducing systemic T cell responses and protecting against heterologous infection.

Quadrivalent mRNA vaccine encoding HA from four seasonal influenza viruses

Self-amplifying mRNA (SAM) vaccines expressing NP; co-administration of SAM-granulocyte-macrophage colony-stimulating factor (GM-CSF); aimed at inducing NP-specific CD8+ T cells.

Influenza virus vaccines made using a closed linear DNA platform, Doggybone™ DNA (dbDNA), produced by a rapid and scalable cell-free method and encoding NA

Bioreducible cationic polymer, pABOL used for the delivery of a self-amplifying RNA (saRNA) vaccine expressing either haemagglutinin (HA) from H1N1 or H3N2 influenza virus in a prime boost regime

A DNA vaccine designed by fusing influenza virus HA with self-assembled ferritin nanoparticles aimed at providing robust immunogenicity, high protective efficacy and being an effective vaccine with rapid production

LNP-encapsulated chemically modified mRNA vaccines encoding various forms of influenza antigens

A lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccine (mRNA-LNPs) that encodes a consensus full-length HA sequence (H1c)

Nucleoside-modified mRNA-LNP encoding three conserved internal proteins of H1N1 influenza virus, NP, M1, and PB1

T-cell targeted DNA vaccine containing multiple pan-DR- and HLA-A2 restricted, highly conserved influenza epitopes.

Status: Active

DNA plasmid encoding conserved M1 (prime) and soluble recombinant M1 subunit protein (boost); aimed at inducing cellular and humoral immune responses for cross protection against heterosubtypic virus infection.

A novel mRNA-based multiantigen influenza vaccine based on a single mRNA molecule with a tandem of three conserved antigens of influenza A virus, including the ectodomain of the M2 ion channel (M2e), the long alpha helix of haemagglutinin stalk region (LAH), and nucleoprotein (NP)

Two novel composite immunogens containing highly conserved T-cell epitopes of 6 influenza A virus internal antigens (based on consensus amino acid sequences of M1, M2, NP, PA, PB1, and PB2 from approximately 40,000 influenza A virus strains) cloned into 3 sequential constructs; DNA prime vaccine followed by consecutive boosting with intranasal AdC68 viral vector and intramuscular Tiantan vaccinia (TTV) virus vector.

DNA vaccine aimed at inducing an anti-M2e immune response by inserting the sequence for truncated NS1 protein followed by 4xM2e into the expression vector pEx (PTriEx-4).

DNA encoding artificial antigens based on the HA stalk and M2 protein to induce cross-protective humoral and cell-mediated responses.

Needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine encoding HA and NA proteins derived from less glycosylated pandemic H1N1 (2009) and H3N2 (1968) virus strains and nucleoprotein (NP) and matrix proteins (M1 and M2) from a different pandemic H1N1 (1918) strain.

A series of genetic algorithm-based mosaic NA1 (mNA1) designed, then cloned into recombinant DNA and replication-defective Vesicular Stomatitis Virus (VSV) vector

Circular RNA (circRNA) vaccines containing N1, N2, and influenza B virus NA antigens to elicit broad-spectrum NA immunity against heterologous influenza

mRNA encoding H1 and H3 COBRA hemagglutinins (HA) or wild-type (WT) influenza HAs encapsulated in lipid nanoparticles (LNPs)

Novel quadravalent mRNA influenza vaccine encoding hemagglutinin (HA) proteins.

Self-amplifying mRNA vaccine encoding the influenza A virus nucleoprotein that is encapsulated in modified dendron-based nanoparticles.

DNA-encoded vaccine proteins targeting APCs; uses either the ectodomain of NA as an antigen, or HA genes from 16 different HAs representing nearly all of the different HA subtypes (except H1 and H7) and inserts them into a DNA vaccine format; aimed at inducing NA immunity and delivery of the HA protein antigens to MHC class II molecules on APCs.

Nucleoside modified mRNA vaccine constructs encoding either conserved antigens, or hemagglutinin antigens from all 20 known influenza A and B virus subtypes aimed at inducing antigen-specific cellular and humoral immune responses to protect against diverse influenza virus strains.

Adjuvanted multi-antigen DNA vaccine consisting of HA, M2, and NP antigens, administered in 3 sequential doses; aimed at inducing mucosal responses and cross-reactive T cell responses.